ANTIHEMOPHILIC FACTOR HUMAN

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

US Approved Rx (1966)

First approved in 1966

Approval Year

Substance Class	Protein Created by `admin` on `Mon Mar 31 18:40:50 GMT 2025` Edited by `admin` on `Mon Mar 31 18:40:50 GMT 2025`
Protein Type	ENZYME
Protein Sub Type	COAGULATION FACTOR
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	839MOZ74GK
Record Status	`Validated (UNII)`
Record Version

Download

Related Record	Type

Name

Type

Language

FACTORATE

Preferred Name

English

ANTIHEMOPHILIC FACTOR HUMAN

Common Name

English

MONOCLATE-P

Brand Name

English

FACTOR VIII (HUMAN)

Common Name

English

HEMOFIL M

Brand Name

English

FACTOR VIII, HUMAN

Common Name

English

Factor viii (antihaemophilic factor) [WHO-DD]

Common Name

English

BLOOD-COAGULATION FACTOR VIII (HUMAN), GLYCOFORM .ALPHA.

Common Name

English

VONCENTO COMPONENT HUMAN COAGULATION FACTOR VIII

Brand Name

English

HUMAN COAGULATION FACTOR VIII [EP MONOGRAPH]

Common Name

English

HUMAN COAGULATION FACTOR VIII

Common Name

English

ANTIHEMOPHILIC FACTOR VIII HUMAN

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000184167

Created by admin on Mon Mar 31 18:40:50 GMT 2025 , Edited by admin on Mon Mar 31 18:40:50 GMT 2025

EMA ASSESSMENT REPORTS

VONCENTO (AUTHORIZED: HEMOPHILIA A)

Created by admin on Mon Mar 31 18:40:50 GMT 2025 , Edited by admin on Mon Mar 31 18:40:50 GMT 2025

EMA ASSESSMENT REPORTS

VONCENTO (AUTHORIZED: VON WILLEBRAND DISEASES)

Created by admin on Mon Mar 31 18:40:50 GMT 2025 , Edited by admin on Mon Mar 31 18:40:50 GMT 2025

Code System Code Type Description

RXCUI

826070

Created by admin on Mon Mar 31 18:40:50 GMT 2025 , Edited by admin on Mon Mar 31 18:40:50 GMT 2025

PRIMARY

NDF-RT

N0000006037

Created by admin on Mon Mar 31 18:40:50 GMT 2025 , Edited by admin on Mon Mar 31 18:40:50 GMT 2025

PRIMARY

Factor VIII [Chemical/Ingredient]

EVMPD

SUB13813MIG

Created by admin on Mon Mar 31 18:40:50 GMT 2025 , Edited by admin on Mon Mar 31 18:40:50 GMT 2025

PRIMARY

FDA UNII

839MOZ74GK

Created by admin on Mon Mar 31 18:40:50 GMT 2025 , Edited by admin on Mon Mar 31 18:40:50 GMT 2025

PRIMARY

NCI_THESAURUS

C81122

Created by admin on Mon Mar 31 18:40:50 GMT 2025 , Edited by admin on Mon Mar 31 18:40:50 GMT 2025

PRIMARY

DAILYMED

839MOZ74GK

Created by admin on Mon Mar 31 18:40:50 GMT 2025 , Edited by admin on Mon Mar 31 18:40:50 GMT 2025

PRIMARY

RXCUI

203083

Created by admin on Mon Mar 31 18:40:50 GMT 2025 , Edited by admin on Mon Mar 31 18:40:50 GMT 2025

ALTERNATIVE

RxNorm

SMS_ID

100000089110

Created by admin on Mon Mar 31 18:40:50 GMT 2025 , Edited by admin on Mon Mar 31 18:40:50 GMT 2025

PRIMARY

NDF-RT

N0000175979

Created by admin on Mon Mar 31 18:40:50 GMT 2025 , Edited by admin on Mon Mar 31 18:40:50 GMT 2025

PRIMARY

Increased Coagulation Activity [PE]

NDF-RT

N0000007914

Created by admin on Mon Mar 31 18:40:50 GMT 2025 , Edited by admin on Mon Mar 31 18:40:50 GMT 2025

PRIMARY

Blood Coagulation Factors [Chemical/Ingredient]

DRUG BANK

DB13192

Created by admin on Mon Mar 31 18:40:50 GMT 2025 , Edited by admin on Mon Mar 31 18:40:50 GMT 2025

PRIMARY

EVMPD

SUB25591

Created by admin on Mon Mar 31 18:40:50 GMT 2025 , Edited by admin on Mon Mar 31 18:40:50 GMT 2025

PRIMARY

From	To
1_153	1_179
1_248	1_329
1_528	1_554
1_630	1_711
2_184	2_210
2_251	2_255
2_373	2_521
2_526	2_678

Glycosylation Type

HUMAN

Glycosylation Link Type	Site
N	1_41
N	1_239
N	1_582
N	1_757
N	1_784
N	1_828
N	1_900
N	1_943
N	1_963
N	1_1001
N	1_1005
N	1_1055
N	1_1066
N	1_1185
N	1_1255
N	1_1259
N	1_1282
N	1_1300
N	2_37
N	2_162
N	2_470

Related Record Type Details


					63QD0BX9B4

ROVOCTOCOGENE DURPARVOVEC

ENZYME REPLACEMENT->TARGET

Amount:


					28GAR3B45E

WP-1301

ANTIGEN->TARGET

Comments:

Attempts to induce tolerance to Factor VIII to prevent or eliminate the formation of antibodies in patients receiving Factor VIII

Amount:


					7NL2E3F6K3

ENZYME REPLACEMENT->TARGET

Comments:

Emicizumab binds to both the activated coagulation factor IX and to factor X, mediating the activation of the latter. Mimics the function of coagulation factor VIII, which is missing in haemophilia A patients.

Amount:


					28GAR3B45E

WP-1301

TOLEROGEN->TARGET

Comments:

Attempts to induce tolerance to Factor VIII to prevent or eliminate the formation of antibodies in patients receiving Factor VIII

Amount:

ANTIHEMOPHILIC HUMAN PLASMA

SUB_CONCEPT->SUBSTANCE

Amount:

ANTIHEMOPHILIC FACTOR (HUMAN)

SUB_CONCEPT->SUBSTANCE

Amount:

Related Record Type Details


					839MOZ74GK

ANTIHEMOPHILIC FACTOR HUMAN

ACTIVE MOIETY

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
PRODUCTION SOURCE	MANUFACTURING		`T74K1VTI2X` HUMAN PLASMA
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL